Nyheter inom Nordiska SBRT-studiegruppen

Presentationer på internationella och nationella konferenser 2024

ESTRO 2024 

Karlsson K, Rancati T, Lindberg S, Grozman V, Hoffmann L, Khalil A, Marquard Knap M, Bjørn Nielsen T, Starup Jeppesen S, Kristiansen C, Ramberg C, Rogg Lotte V, Drugge N, Nyman J, Josipovic M, Fredberg Persson G, Olofsson J, Bergström P, Rosenbrand H-O, Lödén B, Haraldsson A, Engelholm S, Billiet Charlotte, MD, Lindberg K, Onjukka E. Cox-based prediction model of grade 5 bleeding after SBRT of ultra-centrally located lung tumors. Presenteras 4:e maj 2024 på sessionen: ”Proffered Paper - Radiomics, dose analysis and outcome prediction”

Susanne Nørring Bekke, Susan Blak Nyrup Biancardo, Kristian Boye, Cécile Peucelle, Anders Smedegaard Bertelsen, Lone Hoffmann, Tine Schytte, Mette Pøhl, Gitte Persson Daily adaptive MR-guided SBRT of ultra-central lung tumors (NCT05354596) – first dosimetric results. 

Publikationer i vetenskapliga tidskrifter

MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters.
van Overeem Felter M, Møller PK, Josipovic M, Bekke SN, Bernchou U, Serup-Hansen E, Madsen K, Parikh PJ, Kim J, Geertsen P, Behrens CP, Vogelius IR, Pøhl M, Schytte T, Persson GF
Radiother Oncol 2024 Mar;192():110090

In Regard to Milano et al.
Onjukka E, Karlsson K, Lindberg K
Int J Radiat Oncol Biol Phys 2024 Mar;118(4):1144

Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
Lindberg S, Grozman V, Karlsson K, Onjukka E, Lindbäck E, Jirf KA, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Møller DS, Hoffmann L, Knap MM, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Hagen RK, Frøland AS, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R, Lindberg K
Int J Radiat Oncol Biol Phys 2023 Dec;117(5):1222-1231

Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases.
Lindberg S, Onjukka E, Wersäll P, Staff C, Lewensohn R, Masucci G, Lindberg K
Clin Transl Radiat Oncol 2022 Sep;36():91-98

Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
Hoffmann L, Persson GF, Nygård L, Nielsen TB, Borrisova S, Gaard-Petersen F, Josipovic M, Khalil AA, Kjeldsen R, Knap MM, Kristiansen C, Møller DS, Ottosson W, Sand H, Thing R, Pøhl M, Schytte T
Radiother Oncol 2022 Jun;171():53-61

Medical consequences of radiation exposure of the bronchi-what can we learn from high-dose precision radiation therapy?
Lindberg K, Onjukka E
J Radiol Prot 2021 Nov;41(4):

Estimation of delivered dose to lung tumours considering setup uncertainties and breathing motion in a cohort of patients treated with stereotactic body radiation therapy.
Karlsson K, Lax I, Lindbäck E, Grozman V, Lindberg K, Wersäll P, Poludniowski G
Phys Med 2021 Aug;88():53-64

The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, Persson GF, Josipovic M, Khalil AA, Moeller DS, Nyman J, Drugge N, Bergström P, Olofsson J, Rogg LV, Ramberg C, Kristiansen C, Jeppesen SS, Nielsen TB, Lödén B, Rosenbrand HO, Engelholm S, Haraldsson A, Billiet C, Lewensohn R
J Thorac Oncol 2021 Jul;16(7):1200-1210

Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects.
Grozman V, Onjukka E, Wersäll P, Lax I, Tsakonas G, Nyren S, Lewensohn R, Lindberg K
Acta Oncol 2021 Mar;60(3):305-311

Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions.
Lindberg K, Grozman V, Lindberg S, Onjukka E, Lax I, Lewensohn R, Wersäll P
Acta Oncol 2019 Aug;58(8):1178-1186

Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience.
Lindberg K, Nyman J, Riesenfeld Källskog V, Hoyer M, Lund JÅ, Lax I, Wersäll P, Karlsson K, Friesland S, Lewensohn R
Acta Oncol 2015 ;54(8):1096-104

Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy.
Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, Lewensohn R, Wersäll P
Radiother Oncol 2011 Nov;101(2):260-6

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.
Nyman J, Hallqvist A, Lund JÅ, Brustugun OT, Bergman B, Bergström P, Friesland S, Lewensohn R, Holmberg E, Lax I
Radiother Oncol 2016 Oct;121(1):1-8

Presentationer på internationella och nationella konferenser (2021-2023)

ESTRO 2023 

Lindbäck E, Al Jirf K, Hoffman L, Sloth Moeller D, Karlsson K, Nyberg Thomsen S, Lindberg K, Ahmed Khalil A, Uzan J, Onjukka E. SBRT for central lung lesions: large biological delivered dose deviations for the bronchi

ESTRO 2022

Hoffmann L, Persson GF, Nygård L, Nielsen TB, Borrisova S, Gaard-Petersen F, Josipovic M, Khalil AA, Kjeldsen R, Knap MM, Kristiansen C, Møller DS, Ottosson W, Sand H, Thing R, Pøhl M & Schytte T. Pre-study QA reduces delineation errors and minimize dose to OAR in a central lung tumour SBRT trial. 

Svenskt nationellt strålmöte 2023

Muntlig presentation av ”Stereotaktisk strålbehandling av centrala lungtumörer - HILUS-studierna”

ELCC 2021

Hallqvist A, Koyi H, dePetris L, Lindberg K, Farooqi S, Helland Å, Wikstrom A, Johansson M, Planck M, Lindberg L, Yksnøy O, Grønberg B.H, Helbekkmo N, Nyman J. Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). Journal of Thoracic Oncology Vol.16No.4S:S729–S736, 63MO. (Länk: Safety Analysis Shows that Durvalumab Treatment After SBRT (esmo.org)

Organisationer och företag som stöttar Nordiska SBRT-studiegruppens arbete och studier

Följande organisationer och företag har bidragit med ekonomisk stöttning som möjliggjort gruppens arbete med specifika studier. Många av bidragen har även möjliggjort att gruppen expanderat genom utbildning av kliniskt verksamma doktorander.

• Cancerfonden
• Cancerföreningen
• Nordforsk
• Amgen
• KI-fonder
• Svenska Läkaresällskapet
• Region Stockholm (ALF-medel)
• Nordforsk 
• Varian Medical Systems 
• Villadsens Family Foundation 
• Danish Cancer Society
• Independant Researh Foundation Denmark
• The Danish National Research Center for Radiotherapy, Danish Cancer Society and Danish Comprehensive Cancer Center.